The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1290
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults,1 has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.

IRRITABLE BOWEL SYNDROME — IBS, which is characterized by chronic abdominal pain or discomfort and altered bowel habits, has been reported to occur in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS-C has generally been treated with diet and fiber when symptoms are mild and with over-the-counter stool softeners and laxatives when symptoms are moderate. The serotonin partial agonist tegaserod (when it was available) was used when constipation ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
Article code: 1290b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian